Related Experiment Videos
Human fascioliasis successfully treated with triclabendazole
1Elizabeth Macarthur Agricultural Institute, NSW Agriculture, Camden, Australia.
Australian and New Zealand Journal of Medicine
|February 1, 1992
Summary
Human fascioliasis, a liver fluke infection, is rare in Australia. Triclabendazole effectively treated a patient unresponsive to other drugs, suggesting it as the preferred therapy for human liver fluke infections.
Area of Science:
- Veterinary Medicine
- Infectious Diseases
- Parasitology
Background:
- Fascioliasis, caused by Fasciola hepatica, is common in Australian livestock.
- Human infections are infrequent, and optimal treatment remains unclear.
- Existing therapies like praziquantel, mebendazole, and albendazole have shown limited success.
Observation:
- A case report details a patient with fascioliasis in Australia.
- The patient received multiple high-dose treatments with praziquantel, mebendazole, and albendazole without success.
- The infection persisted despite conventional treatments.
Findings:
- Successful elimination of Fasciola hepatica infection was achieved with triclabendazole.
- The patient received two 900 mg (12 mg/kg) doses of triclabendazole, two days apart.
- No adverse side effects were reported following triclabendazole administration.
Implications:
- Triclabendazole demonstrates high efficacy in treating human fascioliasis.
- This case, along with recent literature, supports triclabendazole as the drug of choice.
- Further research and clinical guidelines are needed to establish triclabendazole's role in human fascioliasis management.